ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,557Medicare Part D Prescriptions Filled, Including Refills

Rank: 119 out of 1006

$650K Total Retail Price of All Prescriptions

Rank: 130 out of 1006

440 Patients Receiving at Least One Drug in Part D
93%Patients 65 Years and Older
42% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Connecticut
Lower avg

Schedule Two
Controlled Substances

14% of this provider’s 440 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

5% of this provider’s 440 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Risky Drugs to Seniors

1% of this provider’s 9,220 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

29% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$68 was the average price of a prescription from this provider, compared to $71 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Connecticut
LEVOTHYROXINE SODIUM 543 515 1 2
SIMVASTATIN 368 345 2 1
FUROSEMIDE 313 313 3 6
LISINOPRIL 295 290 4 3
AMLODIPINE BESYLATE 287 287 5 4
WARFARIN SODIUM 255 255 6 8
OMEPRAZOLE 236 230 7 9
ZOLPIDEM TARTRATE 222 221 8 14
METFORMIN HCL 198 195 9 10
HYDROCHLOROTHIAZIDE 194 192 10 11
ATORVASTATIN CALCIUM 185 172 11 5
FENTANYL 149 148 S2 12 74
LISINOPRIL-HYDROCHLOROTHIAZIDE 142 142 13 38
CRESTOR 141 141 14 18
METOPROLOL SUCCINATE 136 132 15 12
METOPROLOL TARTRATE 134 130 16 7
ATENOLOL 133 126 17 13
LOSARTAN POTASSIUM 128 127 18 22
DONEPEZIL HCL 127 127 19 17
GABAPENTIN 124 124 20 20
CYMBALTA 117 117 21 41
CITALOPRAM HBR 117 117 21 24
LIDODERM 110 110 23 66
MIRTAZAPINE 109 109 24 26
BYSTOLIC 104 104 25 84
LANTUS 101 101 26 43
SPIRIVA 98 98 27 48
OXYCODONE-ACETAMINOPHEN 95 94 S2 28 57
SERTRALINE HCL 91 87 29 19
MELOXICAM 89 89 30 67
TAMSULOSIN HCL 80 76 31 23
CARVEDILOL 74 74 32 36
FLUTICASONE PROPIONATE 73 68 33 55
ALLOPURINOL 70 70 34 31
EXELON 69 69 35 99
CELEBREX 68 68 36 90
LOSARTAN-HYDROCHLOROTHIAZIDE 65 63 37 81
SPIRONOLACTONE 65 65 37 71
ADVAIR DISKUS 64 64 39 37
PREDNISONE 58 56 40 33
DIOVAN 56 56 41 16
LIPITOR 56 56 41 47
ALENDRONATE SODIUM 55 55 43 29
PAROXETINE HCL 52 48 44 62
LANTUS SOLOSTAR 51 43 45 93
TRAZODONE HCL 51 51 45 21
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.